Future preclinical studies could use tumour models with high hypoxic burden to assess whether TH‐302 could improve tumour control and enhance the efficacy of combined radiotherapy and anti‐PD‐1/PD‐L1 antibodies. This evidence concerns the gene CD274 and neoplasm.